Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022
About Post-Traumatic Stress Disorder (PTSD) Therapeutics
PTSD) therapeutics include drugs that are used in the treatment of PTSD.
Technavio’s analysts forecast the global post-traumatic stress disorder (PTSD) therapeutics market to grow at a CAGR of 1.26% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global post-traumatic stress disorder (PTSD) therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of post-traumatic stress disorder (PTSD) therapeutics.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022
Technavio recognizes the following companies as the key players in the global post-traumatic stress disorder (PTSD) therapeutics market: GlaxoSmithKline, Pfizer , Eli Lilly and Company, H. Lundbeck
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Emerging therapies for PTSD treatment Many pharmacologic agents are being tested as novel pharmacotherapies for PTSD. Some of the promising agents gaining increasing R&D focus include MDMA, ketamine, and glucocorticoids. MAPS is a non-profit research and educational organization that is funding the clinical trials of MDMA as a tool to assist psychotherapy for the treatment of PTSD. In its Phase II trial with 107 participants, it found that 61% of the participants are no longer qualified for PTSD after three sessions of MDMA-assisted psychotherapy, two months after the treatment. At the 12-month follow-up, 68% participants no longer had PTSD. All participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.”
According to the report, one of the major drivers for this market is Increasing initiatives by public and private organizations. Several public and private organizations are taking initiatives to raise awareness about PTSD and improve access to its treatment. For instance, to bring greater awareness about PTSD, the US Senate has designated June 27th as the national PTSD awareness day.
Further, the report states that one of the major factors hindering the growth of this market is Unmet need for existing therapies. The PTSD medications currently approved by the FDA for the treatment of PTSD (paroxetine and sertraline) do not improve the full range of its symptoms. They show little evidence of treatment effect in men and lack clinical evidence of efficacy in people whose traumatic event was combat-related and carry suicidality warnings. Furthermore, the approved SSRIs and SNRIs have been associated with mild to moderate side effects such as upset stomach, sweating, headache, dizziness, and sexual side effects such as decreased desire to have sex or difficulty in having an orgasm.
GlaxoSmithKline, Pfizer , Eli Lilly and Company, H. Lundbeck
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook